Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

Miljenko V. Pilepich, Kathryn Winter, Madhu J. John, John B. Mesic, William Sause, Phillip Rubin, Colleen Lawton, Mitchell Machtay, David Grignon

Research output: Contribution to journalArticle

706 Citations (Scopus)

Abstract

Purpose: To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve locoregional control and ultimately survival. Methods and Materials: The study was conducted from 1987 to 1991. Eligible patients were those with bulky tumors (T2-T4) with or without pelvic lymph node involvement and without evidence of distant metastases. They were randomized to receive goserelin, 3.6 mg every 4 weeks; and flutamide, 250 mg t.i.d. for 2 months before radiation therapy and during radiation therapy (Arm I), or radiation therapy alone (Arm II). Of 471 randomized patients, 456 were evaluable: 226 on Arm I and 230 on Arm II. Results: As of November 1999, the median follow-up has reached 6.7 years for all patients and 8.6 years for alive patients. At 8 years, androgen ablation has been associated with an improvement in local control (42% vs. 30%, p = 0.016), reduction in the incidence of distant metastases (34% vs. 45%, p = 0.04), disease-free survival (33% vs. 21%, p = 0.004), biochemical disease-free survival = PSA

Original languageEnglish (US)
Pages (from-to)1243-1252
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume50
Issue number5
DOIs
StatePublished - Aug 1 2001
Externally publishedYes

Fingerprint

deprivation
Radiation Oncology
Androgens
Prostate
radiation therapy
Radiotherapy
cancer
Carcinoma
tumors
metastasis
ablation
Disease-Free Survival
Goserelin
Neoplasm Metastasis
Flutamide
Neoplasms
lymphatic system
incidence
Lymph Nodes
Survival

Keywords

  • Carcinoma of the prostate
  • Hormonal management
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. / Pilepich, Miljenko V.; Winter, Kathryn; John, Madhu J.; Mesic, John B.; Sause, William; Rubin, Phillip; Lawton, Colleen; Machtay, Mitchell; Grignon, David.

In: International Journal of Radiation Oncology Biology Physics, Vol. 50, No. 5, 01.08.2001, p. 1243-1252.

Research output: Contribution to journalArticle

Pilepich, Miljenko V. ; Winter, Kathryn ; John, Madhu J. ; Mesic, John B. ; Sause, William ; Rubin, Phillip ; Lawton, Colleen ; Machtay, Mitchell ; Grignon, David. / Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. In: International Journal of Radiation Oncology Biology Physics. 2001 ; Vol. 50, No. 5. pp. 1243-1252.
@article{706a33f208f749c39ded19c880c72170,
title = "Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate",
abstract = "Purpose: To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve locoregional control and ultimately survival. Methods and Materials: The study was conducted from 1987 to 1991. Eligible patients were those with bulky tumors (T2-T4) with or without pelvic lymph node involvement and without evidence of distant metastases. They were randomized to receive goserelin, 3.6 mg every 4 weeks; and flutamide, 250 mg t.i.d. for 2 months before radiation therapy and during radiation therapy (Arm I), or radiation therapy alone (Arm II). Of 471 randomized patients, 456 were evaluable: 226 on Arm I and 230 on Arm II. Results: As of November 1999, the median follow-up has reached 6.7 years for all patients and 8.6 years for alive patients. At 8 years, androgen ablation has been associated with an improvement in local control (42{\%} vs. 30{\%}, p = 0.016), reduction in the incidence of distant metastases (34{\%} vs. 45{\%}, p = 0.04), disease-free survival (33{\%} vs. 21{\%}, p = 0.004), biochemical disease-free survival = PSA",
keywords = "Carcinoma of the prostate, Hormonal management, Radiotherapy",
author = "Pilepich, {Miljenko V.} and Kathryn Winter and John, {Madhu J.} and Mesic, {John B.} and William Sause and Phillip Rubin and Colleen Lawton and Mitchell Machtay and David Grignon",
year = "2001",
month = "8",
day = "1",
doi = "10.1016/S0360-3016(01)01579-6",
language = "English (US)",
volume = "50",
pages = "1243--1252",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

AU - Pilepich, Miljenko V.

AU - Winter, Kathryn

AU - John, Madhu J.

AU - Mesic, John B.

AU - Sause, William

AU - Rubin, Phillip

AU - Lawton, Colleen

AU - Machtay, Mitchell

AU - Grignon, David

PY - 2001/8/1

Y1 - 2001/8/1

N2 - Purpose: To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve locoregional control and ultimately survival. Methods and Materials: The study was conducted from 1987 to 1991. Eligible patients were those with bulky tumors (T2-T4) with or without pelvic lymph node involvement and without evidence of distant metastases. They were randomized to receive goserelin, 3.6 mg every 4 weeks; and flutamide, 250 mg t.i.d. for 2 months before radiation therapy and during radiation therapy (Arm I), or radiation therapy alone (Arm II). Of 471 randomized patients, 456 were evaluable: 226 on Arm I and 230 on Arm II. Results: As of November 1999, the median follow-up has reached 6.7 years for all patients and 8.6 years for alive patients. At 8 years, androgen ablation has been associated with an improvement in local control (42% vs. 30%, p = 0.016), reduction in the incidence of distant metastases (34% vs. 45%, p = 0.04), disease-free survival (33% vs. 21%, p = 0.004), biochemical disease-free survival = PSA

AB - Purpose: To test the hypothesis that androgen ablation before and during radiotherapy for locally advanced carcinoma of the prostate may, by reducing tumor bulk and enhancing tumor cell kill, improve locoregional control and ultimately survival. Methods and Materials: The study was conducted from 1987 to 1991. Eligible patients were those with bulky tumors (T2-T4) with or without pelvic lymph node involvement and without evidence of distant metastases. They were randomized to receive goserelin, 3.6 mg every 4 weeks; and flutamide, 250 mg t.i.d. for 2 months before radiation therapy and during radiation therapy (Arm I), or radiation therapy alone (Arm II). Of 471 randomized patients, 456 were evaluable: 226 on Arm I and 230 on Arm II. Results: As of November 1999, the median follow-up has reached 6.7 years for all patients and 8.6 years for alive patients. At 8 years, androgen ablation has been associated with an improvement in local control (42% vs. 30%, p = 0.016), reduction in the incidence of distant metastases (34% vs. 45%, p = 0.04), disease-free survival (33% vs. 21%, p = 0.004), biochemical disease-free survival = PSA

KW - Carcinoma of the prostate

KW - Hormonal management

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0035424063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035424063&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(01)01579-6

DO - 10.1016/S0360-3016(01)01579-6

M3 - Article

VL - 50

SP - 1243

EP - 1252

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -